Table 1.
Study sample characteristics
| Characteristic | F5L Family Study (N = 251) | MARTHA Study (N = 1033) | AtheroGene Study (N = 892) |
|---|---|---|---|
| Female sex, N (%) | 126 (50.2) | 684 (66.2) | 200 (22.4) |
| Mean age in years (SD) | 40.5 (18.0) | 47.5 (15.2) | 61.1 (9.8) |
| History of thrombosis*, N (%) | 15 (6.0) | 1033 (100) | 271 (30.4) |
| Mean TFPI level in ng mL−1 (SD) | 8.3 (3.8) | 13.5 (6.5) | 24.8 (40.4) |
| F5L mutation carrier, N (%) | 63 (25.1) | 237 (22.9) | ND |
| Current smoker, N (%) | 61 (24.3) | 234 (22.7) | 360 (40.3) |
| Female hormone therapy use, N (%) | 18 (7.2) | 66 (6.4) | ND |
| Mean body mass index in kg m−2 (SD) | 26.9 (5.9) | 25.4 (4.8) | 27.6 (3.7) |
| Antiplatelet use, N (%) Anticoagulant use, N (%) | 17 (6.8) | 69 (6.7) | 753 (84.4) |
| Vitamin K antagonists | 8 (3.2) | 235 (22.7) | ND |
| Heparin (low molecular weight or unfractioned), N (%) | 0 | 0 | 359 (40.2) |
F5L, factor V Leiden mutation; ND, not determined; SD, standard deviation; TFPI, tissue factor pathway inhibitor.
*
Thrombosis is defined as venous thromboembolism in the F5L Family Study and in the MARTHA Study, and as myocardial infarction in the AtheroGene Study.